StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Kymera Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -396.0%. For fiscal 2025 it was -891.1%, against -555.8% the year before. The highest annual figure on record is -136.1% in fiscal 2020.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-891.1%−335.3
FY2024Dec 31, 2024-555.8%−345.2
FY2023Dec 31, 2023-210.6%+133.8
FY2022Dec 31, 2022-344.4%−206.3
FY2021Dec 31, 2021-138.0%−2.0
FY2020Dec 31, 2020-136.1%+1302.4
FY2019Dec 31, 2019-1438.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-116.3%+620.5
Q1 FY2026Mar 31, 2026-244.9%+91.9
Q4 FY2025Dec 31, 2025-3411.0%−2318.8
Q3 FY2025Sep 30, 2025-3347.4%−1419.4
Q2 FY2025Jun 30, 2025-736.8%−538.3
Q1 FY2025Mar 31, 2025-336.8%+225.4
Q4 FY2024Dec 31, 2024-1092.2%−1051.8
Q3 FY2024Sep 30, 2024-1927.9%−711.6
Q2 FY2024Jun 30, 2024-198.5%+64.2
Q1 FY2024Mar 31, 2024-562.2%−83.3
Q4 FY2023Dec 31, 2023-40.3%+199.0
Q3 FY2023Sep 30, 2023-1216.3%−746.4
Q2 FY2023Jun 30, 2023-262.7%+91.7
Q1 FY2023Mar 31, 2023-478.8%−95.0
Q4 FY2022Dec 31, 2022-239.4%−16.8
Q3 FY2022Sep 30, 2022-469.9%−329.1
Q2 FY2022Jun 30, 2022-354.4%−220.9
Q1 FY2022Mar 31, 2022-383.8%−313.4
Q4 FY2021Dec 31, 2021-222.5%−122.6
Q3 FY2021Sep 30, 2021-140.8%−85.2
Q2 FY2021Jun 30, 2021-133.5%+298.1
Q1 FY2021Mar 31, 2021-70.4%+257.7
Q4 FY2020Dec 31, 2020-100.0%+542.8
Q3 FY2020Sep 30, 2020-55.6%+1192.9
Q2 FY2020Jun 30, 2020-431.6%–
Q1 FY2020Mar 31, 2020-328.1%–
Q4 FY2019Dec 31, 2019-642.8%–
Q3 FY2019Sep 30, 2019-1248.5%–

More Kymera Therapeutics figures

See a number that looks wrong?